Photo does not depict actual patient
ANDEMBRY Provides Significant Reduction in HAE Attacks
A median reduction of >99% was calculated because at least half of the ANDEMBRY-treated patients experienced a complete reduction in monthly HAE attack rates compared to placebo. Patients receiving ANDEMBRY in the clinical trial experienced an adjusted average of 89% (LS; least squares) reduction in monthly HAE attack rate compared to placebo.
* With all HAE medications, attacks can still occur. Patients should always have a rescue medication.
† At 6 months.
LS, least squares
ANDEMBRY, THE FIRST AND ONLY ONCE-MONTHLY HAE PROPHYLAXIS TREATMENT FROM THE START FOR ALL PATIENTS
- Monthly dosing from the start for all patients 12 years and older
- Subcutaneous self-injection delivered in ≤15 seconds via a convenient autoinjector
- No reports of injection-site pain§
§ In the VANGUARD pivotal phase 3 trial. Patients in the pivotal study and open-label extension study experienced injection-site redness, itching, and bruising.
Innovation in Action
Only ANDEMBRY, a monoclonal antibody, inhibits FXIIa at the top of the HAE pathway
